Compare Inovio Pharmaceuticals Inc (INO) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while S&P500 ETF trades at $778.31 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 7322.8× Inovio Pharmaceuticals Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and S&P500 ETF for 205 Days on average.
| INO | SPY | |
|---|---|---|
Market Cap | $112.19M | $821.54B |
Volume | 3,201,278 | 40,070,358 |
Sector | Health | — |
52-Week High | $2.65 | $779.14 |
52-Week Low | $0.66 | $631.99 |
Typical Hold Time | 43 Days | 205 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
SPY, the SPDR S&P 500 ETF, trades at $778.54, up 0.16% on the day, with a bullish technical signal driven by moving averages. The ETF is positioned near resistance at $777, with support at $771. Recent news highlights mixed sentiment, with some articles noting strong profit growth expectations for the S&P 500 in 2026 but potential headwinds from margin debt and slowing growth forecasts for 2027.
The outlook for SPY remains tied to broader market trends, with opportunities from potential year-end rallies and strong corporate earnings, but risks include macroeconomic volatility and elevated valuations. Investor sentiment is cautious amid warnings about market collapses and shifting profit growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
